This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...
Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and ...
The initial public offering (IPO) market showed signs of life for the first time in more than a month as Boston-based Avalyn ...
Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
It’s another busy day in the world of initial public offerings. Companies are making moves to go public, and keeping up with ...
Backed by Novo Holdings and multiple other prominent investors, the biotech is developing what it’s positioning as superior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results